Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis

A global view of the interplay between non-alcoholic fatty liver disease and diabetes

(2022) Norbert Stefan et al.   Lancet Diabetes & Endocrinology

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease

(2022) Lei Miao et al.   Journal of Clinical and Translational Hepatology

Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease

(2022) Nicholas W. S. Chew et al.   Current Atherosclerosis Reports

Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals

(2022) Jingxuan Quek et al.   Endocrine Practice

Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?

(2022) Zobair M. Younossi et al.   HEPATOLOGY

Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals

(2022) Kai En Chan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis

(2022) Darren Jun Hao Tan et al.   LANCET ONCOLOGY

Global multi-stakeholder endorsement of the MAFLD definition

(2022) Nahum Méndez-Sánchez et al.   Lancet Gastroenterology & Hepatology

The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease

(2022) Cheng Han Ng et al.   Clinical and Molecular Hepatology

NAFLD versus MAFLD: Prevalence, Outcomes and Implications of a Change in Name

(2022) Cheng Han Ng et al.   Clinical and Molecular Hepatology

The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting

(2022) Aaron P. Thrift et al.   Clinical Gastroenterology and Hepatology

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

(2021) Alessandro Mantovani et al.   Metabolites

The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments

(2021) Giovanni Targher et al.   Nature Reviews Gastroenterology & Hepatology

Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease

(2021) Soo Lim et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know

(2021) Mark D. Muthiah et al.   DIABETES OBESITY & METABOLISM

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease

(2021) Diana Barb et al.   Obesity

Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver

(2021) Mi Na Kim et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD

(2021) Grace En Hui Lim et al.   Clinical Gastroenterology and Hepatology

Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials

(2021) Cheng Han Ng et al.   Endocrine Practice

Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?

(2021) Xu Chen et al.   JOURNAL OF HEPATOLOGY

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

NAFLD 2020: The State of the Disease

(2020) Thomas G. Cotter et al.   GASTROENTEROLOGY

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease

(2020) Donghee Kim et al.   Clinical Gastroenterology and Hepatology

Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories

(2020) Stefano Ciardullo et al.   HYPERTENSION

Concordance of MAFLD and NAFLD diagnostic criteria in “real‐world” data

(2020) Giovanni Targher   LIVER INTERNATIONAL

Clinical utility of the MAFLD definition

(2020) Kenneth I. Zheng et al.   JOURNAL OF HEPATOLOGY

The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis

(2019) Zobair M. Younossi et al.   JOURNAL OF HEPATOLOGY

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

(2014) L. Fedchuk et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Chronic kidney disease

(2011) Andrew S Levey et al.   LANCET